Patents by Inventor Mario SANCHES
Mario SANCHES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965036Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: GrantFiled: February 24, 2021Date of Patent: April 23, 2024Assignee: Zymeworks BC Inc.Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Publication number: 20240115603Abstract: Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor.Type: ApplicationFiled: October 8, 2020Publication date: April 11, 2024Inventors: Gesa Volkers, Megan Fuller, Martin J. Boulanger, Surjit Bhimarao Dixit, Brad Nelson, Mario Sanches, Bianca Loveless
-
Publication number: 20230118302Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: ApplicationFiled: April 25, 2022Publication date: April 20, 2023Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Publication number: 20220251242Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: February 25, 2022Publication date: August 11, 2022Inventors: Mario SANCHES, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A.L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
-
Publication number: 20220227840Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: January 24, 2022Publication date: July 21, 2022Inventors: Adam Louis CORPER, Dunja UROSEV, Stacey A.L. TOM-YEW, Dustin Weyland Blue BLEILE, Thomas SPRETER VON KREUDENSTEIN, Surjit DIXIT, Paula Irene LARIO, Mario SANCHES
-
Patent number: 11325981Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: GrantFiled: June 18, 2018Date of Patent: May 10, 2022Assignee: Zymeworks Inc.Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Patent number: 11306156Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: GrantFiled: May 29, 2015Date of Patent: April 19, 2022Assignee: ZYMEWORKS INC.Inventors: Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
-
Patent number: 11286293Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: GrantFiled: September 5, 2018Date of Patent: March 29, 2022Assignee: ZYMEWORKS, INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 11248037Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.Type: GrantFiled: May 21, 2019Date of Patent: February 15, 2022Assignee: ZYMEWORKS INC.Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
-
Publication number: 20210403598Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: ApplicationFiled: February 24, 2021Publication date: December 30, 2021Inventors: Nina E. Weisser, Gordon Yiu Kon NG, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Publication number: 20210355239Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.Type: ApplicationFiled: April 27, 2021Publication date: November 18, 2021Inventors: Dunja UROSEV, Stacey A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
-
Patent number: 11161915Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.Type: GrantFiled: October 7, 2016Date of Patent: November 2, 2021Assignee: ZYMEWORKS INC.Inventors: Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
-
Publication number: 20210309760Abstract: Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: June 9, 2021Publication date: October 7, 2021Inventors: Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 11078296Abstract: Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: GrantFiled: February 14, 2018Date of Patent: August 3, 2021Assignee: ZYMEWORKS INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 10947319Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: GrantFiled: November 27, 2014Date of Patent: March 16, 2021Assignee: Zymeworks Inc.Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Publication number: 20190375823Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.Type: ApplicationFiled: May 21, 2019Publication date: December 12, 2019Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
-
Publication number: 20190367612Abstract: The present disclosure provides a novel antibody that binds to human GPRC5D; a molecule with human GPRC5D binding activity, which comprises the antibody; and an anti-tumor pharmaceutical composition comprising the antibody or the molecule as an active.Type: ApplicationFiled: June 2, 2018Publication date: December 5, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Takashi CHAEN, Toshiaki OHTSUKA, Kenji IIDA, Kensuke NAKAMURA, Takahide ABURATANI, Junya ICHIKAWA, Shota KUDO, Chayne Lee PISCITELLI, Mario SANCHES
-
Publication number: 20190338048Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.Type: ApplicationFiled: October 7, 2016Publication date: November 7, 2019Inventors: Dunja UROSEV, Stacy A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
-
Patent number: 10358479Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.Type: GrantFiled: January 19, 2016Date of Patent: July 23, 2019Assignee: ZYMEWORKS INC.Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
-
Publication number: 20190085055Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: September 5, 2018Publication date: March 21, 2019Inventors: Adam Louis CORPER, Dunja UROSEV, Stacey A.L. TOM-YEW, Dustin Weyland Blue BLEILE, Thomas SPRETER VON KREUDENSTEIN, Surjit DIXIT, Paula Irene LARIO, Mario SANCHES